Search company, investor...

Pacira Biosciences

pacira.com

Founded Year

2007

Stage

IPO | IPO

Total Raised

$111.25M

Date of IPO

4/13/2012

Market Cap

1.81B

Stock Price

40.57

About Pacira Biosciences

Pacira Biosciences is focused on formulating, developing and manufacturing controlled-release injectable products based on two drug delivery platforms: DepoFoam and Biosphere. Currently the Company is generating revenue with two marketed products: DepoCyt for lymphomatous meningitis and DepoDur for the treatment of post-surgical pain.

Headquarters Location

10578 Science Center Drive Suite 125

San Diego, California, 92121,

United States

858-625-2424

Missing: Pacira Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pacira Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Pacira Biosciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Pacira Biosciences in 1 CB Insights research brief, most recently on Sep 3, 2020.

Expert Collections containing Pacira Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pacira Biosciences is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Pacira Biosciences Patents

Pacira Biosciences has filed 46 patents.

The 3 most popular patent topics include:

  • Analgesics
  • Anesthesia
  • Calcium channel blockers
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/19/2022

9/27/2022

Anesthesia, Analgesics, Piperidines, Dosage forms, Calcium channel blockers

Grant

Application Date

5/19/2022

Grant Date

9/27/2022

Title

Related Topics

Anesthesia, Analgesics, Piperidines, Dosage forms, Calcium channel blockers

Status

Grant

Latest Pacira Biosciences News

Pacira gains as Wedbush initiates at Outperform seeing attractive entry point

Jan 31, 2023

naphtalina/iStock via Getty Images The shares of pain therapy developer Pacira BioSciences (NASDAQ: PCRX ) gained in the morning hours Tuesday after Wedbush Securities started its coverage with an Outperform recommendation citing a compelling buying opportunity. Pacira ( PCRX ) has lost more than 37% over the past 12 months, and the analyst Andreas Argyrides argues: “We find the setup for the stock this year creates an attractive buying opportunity.” The analyst points to management efforts to improve the uptake of the company’s non-opioid post-surgical analgesic Exparel and predicts additional upside for his 12-month target of $60 from multiple catalysts this year. Argyrides argues that despite a significant decline in surgical operations last year, Pacira ( PCRX ) improved Exparel sales by more than 7% to ~$537M, thanks to expanded market penetration. However, citing persisting volume headwinds related to elective procedures, Wedbush revises down the 2023 growth forecast for Exparel to a mid-single-digit percentage range from a pandemic-era mid-teens percentage. This month, Seeking Alpha contributor Zach Bristow issued a Hold rating on Pacira ( PCRX ), arguing “more evidence (is) needed to advocate entry at current valuations.” Recommended For You

Pacira Biosciences Frequently Asked Questions (FAQ)

  • When was Pacira Biosciences founded?

    Pacira Biosciences was founded in 2007.

  • Where is Pacira Biosciences's headquarters?

    Pacira Biosciences's headquarters is located at 10578 Science Center Drive, San Diego.

  • What is Pacira Biosciences's latest funding round?

    Pacira Biosciences's latest funding round is IPO.

  • How much did Pacira Biosciences raise?

    Pacira Biosciences raised a total of $111.25M.

  • Who are the investors of Pacira Biosciences?

    Investors of Pacira Biosciences include GE Capital, GE Healthcare, Sanderling Ventures, OrbiMed Advisors, MPM Capital and 3 more.

  • Who are Pacira Biosciences's competitors?

    Competitors of Pacira Biosciences include Remedium Bio, PolyPid, EZRA Innovations, Sagent Pharmaceuticals, Critical Pharmaceuticals and 15 more.

Compare Pacira Biosciences to Competitors

C
Core Tech Solutions

Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.

C
Critical Pharmaceuticals

Critical Pharmaceuticals is an advanced drug delivery company with core expertise in delivery of macromolecules such as DNA, proteins, peptides, siRNA and aptamers.

N
Next Breath

Next Breath, LLC is a contract pharmaceutical research and development organization dedicated to pre-clinical identification and evaluation of commercially viable respiratory and nasal drug delivery platforms. NB's business will discover and exploit optimal drug and delivery device combinations that will increase the company's partners' probability of success when their products advance into human clinical trials and the marketplace. Next Breath seeks to meet the pharmaceutical industry's outsourcing needs and to provide intellectual expertise to biotechnology companies that are developing inhalation products.

E
Eratech srl

Eratech is a drug development company specialized in the field of inhalation drug delivery via nasal and pulmonary administration, for local and systemic therapies. Eratech offers to its clients the following selection of product development support services: Pharmacological-Toxicological, Pharmaceutical Development, Clinical Trials, Regulatory Affairs. nnn

T
Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

S
Spherics

Pharmaceutical company focused on applying its oral drug delivery platform to develop products with improved therapeutic profiles

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.